Sanofi-Aventis Research & Development

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised
  2023-503631-18-00 Phase III 2 countries TERIFLUNOMIDE; TOLEBRUTINIB
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended
  2023-505394-32-00 Phase III 13 countries BELUMOSUDIL MESILATE
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended
  2023-504331-41-00 Phase III 9 countries DUPILUMAB
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended
  2022-502188-39-00 Phase II 8 countries AMLITELIMAB
• Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended
  2022-500290-14-01 Phase II 11 countries ECLITASERTIB
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 Phase III 7 countries AMLITELIMAB
• Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended
  2023-505803-22-00 Phase II 7 countries AMLITELIMAB
• A study in healthy male adult participants to assess how much test medicine (SAR443820) is taken up, broken down and removed by the body whe… Ended
  2022-502534-23-00 Phase I/II 1 country SAR443820
• Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d… Ended
  2024-518403-22-00 Phase IV 1 country
• A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment w… Ended
  2022-502414-84-00 Phase I (Other) 2 countries

Showing 1–10 of 10 trials